Ferreira RB - Search Results

1

A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.

Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK. Wang M, et al. Among authors: ferreira rb. Oncogene. 2019 May;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub 2019 Feb 4. Oncogene. 2019. PMID: 30718919

2

Novel agents that downregulate EGFR, HER2, and HER3 in parallel.

Ferreira RB, Law ME, Jahn SC, Davis BJ, Heldermon CD, Reinhard M, Castellano RK, Law BK. Ferreira RB, et al. Oncotarget. 2015 Apr 30;6(12):10445-59. doi: 10.18632/oncotarget.3398. Oncotarget. 2015. PMID: 25865227 Free PMC article.

3

CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.

Law ME, Ferreira RB, Davis BJ, Higgins PJ, Kim JS, Castellano RK, Chen S, Luesch H, Law BK. Law ME, et al. Among authors: ferreira rb. Breast Cancer Res. 2016 Aug 5;18(1):80. doi: 10.1186/s13058-016-0741-1. Breast Cancer Res. 2016. PMID: 27495374 Free PMC article.

4

Selective and Sequential Aminolysis of Benzotrifuranone: Synergism of Electronic Effects and Ring Strain Gradient.

Baker MB, Ferreira RB, Tasseroul J, Lampkins AJ, Al Abbas A, Abboud KA, Castellano RK. Baker MB, et al. Among authors: ferreira rb. J Org Chem. 2016 Oct 7;81(19):9279-9288. doi: 10.1021/acs.joc.6b01867. Epub 2016 Sep 15. J Org Chem. 2016. PMID: 27580412

5

Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK. Ferreira RB, et al. Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952. Oncotarget. 2017. PMID: 28423644 Free PMC article.

6

Benzotrifuran (BTFuran): a building block for π-conjugated systems.

Ferreira RB, Figueroa JM, Fagnani DE, Abboud KA, Castellano RK. Ferreira RB, et al. Chem Commun (Camb). 2017 Aug 24;53(69):9590-9593. doi: 10.1039/c7cc04505k. Chem Commun (Camb). 2017. PMID: 28809405

7

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.

Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, Kraus M, Bader J, Ferreira RB, Castellano RK, Law BK, Driessen C. Besse L, et al. Among authors: ferreira rb. Haematologica. 2019 Sep;104(9):e415-e419. doi: 10.3324/haematol.2018.207704. Epub 2019 Feb 21. Haematologica. 2019. PMID: 30792209 Free PMC article. No abstract available.

8

Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.

Wang M, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Ferreira RB, Chiang CW, Guryanova OA, Kopinke D, Heldermon CD, Castellano RK, Law BK. Wang M, et al. Among authors: ferreira rb. Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019. Cell Death Discov. 2019. PMID: 31839995 Free PMC article.

9

[No title available]

[No authors listed] [No authors listed] PMID: 33293526

10

Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.

Law ME, Yaaghubi E, Ghilardi AF, Davis BJ, Ferreira RB, Koh J, Chen S, DePeter SF, Schilson CM, Chiang CW, Heldermon CD, Nørgaard P, Castellano RK, Law BK. Law ME, et al. Among authors: ferreira rb. Cancer Lett. 2022 May 28;534:215604. doi: 10.1016/j.canlet.2022.215604. Epub 2022 Mar 2. Cancer Lett. 2022. PMID: 35247515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

192 results

Search Page